Supernus Pharmaceuticals (SUPN) shares fell over 20% in Wednesday's premarket activity after the company said overnight its phase 2b study of SPN-820 in adults with treatment-resistant depression "did not" demonstrate a statistically significant improvement on the primary endpoint.
There was no treatment difference between SPN-820 and placebo in the change from baseline to week 4 for the secondary endpoints, the company said late Tuesday.
The multi-center, double-blind trial examined the efficacy and safety of SPN-820 over four weeks of treatment and then a week of "blinded placebo-washout" in about 250 patients from roughly 40 clinical sites.
Price: 31.71, Change: -8.04, Percent Change: -20.23
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.